Showing 681 - 700 results of 114,462 for search '(( a non decrease ) OR ( 5 ((((wt decrease) OR (nn decrease))) OR (a decrease)) ))', query time: 1.62s Refine Results
  1. 681

    UVB irradiation decreased TM expression in HaCaT cells. by Huey-Chun Huang (429098)

    Published 2013
    “…<p>(A) HaCaT Cells were exposed to UVB irradiation in a dose-response (0, 1.5, 3, 4.5, 6 mJ/cm<sup>2</sup>) Cell viability was examined by trypan blue exclusion. …”
  2. 682
  3. 683
  4. 684
  5. 685
  6. 686
  7. 687
  8. 688
  9. 689

    NAC prevents VMH GI neuron activation by decreased glucose. by Xavier Fioramonti (371172)

    Published 2013
    “…(B) Percentage of VMH GI neurons from S<sup>3</sup>S or I<sup>3</sup>S rats pre-treated or not with NAC which depolarized in response to a 2.5–0.7 mM glucose decrease quantified using changes in FLIPR-MPD fluorescence intensity. *: p<0.05 (Two-way ANOVA; group differences were determined by One-Way ANOVA followed by Bonferoni post-hoc test).…”
  10. 690
  11. 691

    Hematopoietic potential decreases in ESC with down-regulation of junction molecules. by Basha L. Stankovich (207031)

    Published 2011
    “…CD45 expression was analyzed flow cytometrically using anti-CD45 conjugated to PerCP-Cy5.5. Non-viable cells were excluded based on DAPI fluorescence. …”
  12. 692
  13. 693

    Wnt5a expressing tumors demonstrate a decrease in markers of the basal tumor subtype. by Stephanie L. Easter (662168)

    Published 2014
    “…Values are means +/− standard error (n = 6 MMTV-Wnt1, 3 fields per tumor; n = 5 MMTV-Wnt1;MMTV-Wnt5a, 3 fields per tumor). MMTV-Wnt1;MMTV-Wnt5a tumors demonstrated a significant decrease in K6-expressing cells as measured by T-test (* = p<0.05).…”
  14. 694
  15. 695
  16. 696
  17. 697
  18. 698
  19. 699

    Image 5_Behavioral and biochemical changes associated with the analgesic effects of (2R,6R)-hydroxynorketamine alone and in combination with meloxicam following disk puncture in mi... by Vaskar Das (21529538)

    Published 2025
    “…Our finding supports further study of the clinical potential of (2R,6R)-Hydroxynorketamine as a non-opioid analgesic for discogenic back pain.…”
  20. 700